Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

Study Summary

VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.

Conditions

Hypercholesterolemia Hypertriglyceridemia Refractory Hyperlipidemia

Interventions / Drugs

VERVE-201

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment36 participants

Primary Completion—

Lead SponsorVerve Therapeutics, Inc.

Data Retrieved2026-04-11 04:30:55.354419+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.